Chronic central infusion of growth hormone secretagogues: Effects on Fos expression and peptide gene expression in the rat arcuate nucleus

Neuroendocrinology

Volumn 70, Issue 2, 1999, Pages 83-92

  Bailey, Alex R T ^a,c   Giles, Michelle E ^a   Brown, Colin H ^a   Bull, Philip M ^a   Macdonald, Lynn P ^d   Smith, Lynsey C ^a   Smith, Roy G ^b   Leng, Gareth ^a   Dickson, Suzanne L ^d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d NONE

Author keywords

Fos; Growth hormone secretagogues; Growth hormone releasing hormone; In situ hybridisation; Neuropeptide Y; Periventricular nucleus; Somatostatin

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE SECRETAGOGUE; MESSENGER RNA; NEUROPEPTIDE Y; PEPTIDE; SOMATOSTATIN; UNCLASSIFIED DRUG;

ADENOHYPOPHYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARCUATE NUCLEUS; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GROWTH HORMONE RELEASE; IN SITU HYBRIDIZATION; MALE; NERVE CELL; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; RAT;

ANIMALS; ARCUATE NUCLEUS; GENE EXPRESSION REGULATION; GENES, FOS; GROWTH HORMONE; GROWTH HORMONE-RELEASING HORMONE; HORMONES; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INDOLES; INJECTIONS; MALE; NEUROPEPTIDE Y; OLIGOPEPTIDES; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SPIRO COMPOUNDS;

EID: 0032842578     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054462     Document Type: Article

References (40)

1. Bowers CY, Momany FA, Reynolds GA, Hong A: On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984;114:1537-1545.
2. Dickson SL, Leng G, Robinson ICAF: Systemic administration of growth hormone-releasing peptide (GHRP-6) activates hypothalamic arcuate neurones. Neuroscience 1993;53: 303-306.
3. Dickson SL, Luckman SM: Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurones in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6. Endocrinology 1997; 138:771-777.
4. Honda K, Bailey ART, Bull PM, McDonald LP, Dickson SL. Leng G: An electrophysiological and morphological investigation of the projections of GHRP-6-responsive neurons in the rat arcuate nucleus to the median eminence and to the paraventricular nucleus. Neuroscience 1999;90:875-883.
5. Clark JT, Kalra PS, Crowley WR, Kalra SP: Neuropeptide Y and human pancreatic polypeptide stimulate feeding in rats. Endocrinology 1984;115:427-429.
6. Akabayashi A, Watanabe Y, Wahlestedt C, McEwen BS, Paez X, Leibowitz SF: Hypothalamic neuropeptide Y, its gene expression and receptor activity: Relation to circulating corticosterone in adrenalectomized rats. Brain Res 1993;665:201-212.
7. Dickson SL, Leng G, Dyball REJ, Smith RG: Central action of peptide and non-peptide growth hormone secretagogues in the rat. Neuroendocrinology 1995;61:36-43.
8. Bailey ART, Smith RG, Leng G: The non-peptide growth hormone secretagogue, MK-0677, activates hypothalamic arcuate nucleus neurones in vivo. J Neuroendocrinol 1988;10:111-118.
9. Rømer J, Fink-Jensen A, Willesen MG, Kristensen P: Central effects of the growth hormone secretagogue ipamorelin characterized by immunohistochemistry and in situ hybridization for c-fos (abstract P2-227). Proc 80th Annu Meet Endocr Soc, New Orleans, 1998.
10. Patchett AA, Smith RG, Wyvratt MJ: Orally-active growth hormone secretagogues; in Borchardt (ed): Integration of Pharmaceutical Discovery and Development: Case Studies. New York, Plenum Press, 1998, vol 23, pp 525-554.
11. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH: Ipamorelin, a novel, potent and highly selective growth hormone secretagogue. Eur J Endocrinol 1998;139:552-561.
12. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hrenluk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong S-S, Chaung L-Y, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJS, Dean DC, Melillo DG, Patchett AA, Nargund R, Griffin PR, DeMartino JA, Gupta SK, Schaeffer JM, Smith RG, Van der Ploeg LHT: A pituitary gland and hypothalamic receptor that functions in growth hormone release. Science 1996;273:974-977.
13. Clark RG, Carlsson LMS, Trojnar J, Robinson ICAF: The effects of a growth hormone-releasing peptide and growth hormone-releasing factor in conscious and anaesthetized rats. J Neuroendocrinol 1989;1:249-255.
14. Fairhall KM, Mynett A, Smith RG, Robinson ICAF: Consistent GH responses to repeated injections of GH-releasing hexapeptide (GHRP-6) and the non-peptide GH secretagogue, L-692-585. J Endocrinol 1995;145:417-426.
15. McCormick GF, Millard WJ, Badger TM, Bowers CY, Martin JB: Dose-response characteristics of various peptides with growth hormone-releasing activity in the unanesthetized male rat. Endocrinology 1985;117:97-105.
16. Huhn WC, Hartman ML, Pezzoli SS, Thorner MO: Twenty-four-hour growth-hormone (GH)-releasing peptide infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus. J Clin Endocrinol Metab 1993;76:1202-1208.
17. Jaffe CA, Ho PJ, Demottfriberg R, Bowers CY, Barkan AL: Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab 1993;77:1641-1647.
18. Klinger B, Silbergeld A, Deghenghi R, Frenkel J, Laron Z: Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children. Eur J Endocrinol 1996;134:716-719.
19. 2 stimulate growth hormone release through distinct receptor sites.7 J Endocrinol 1991;129:11-19.
20. Svensson J, Lönn L, Jansson J-O, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson B-Å:Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab 1998;83:362-369.
21. Svensson J, Ohlsson C, Jansson J-O, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Baylink D, Mohan S, Bengtsson B-Å: Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males. J Bone Miner Res 1998;13:1158-1166.
22. Arvat E, Camanni F, Ghigo E: Age-related growth hormone-releasing activity of growth hormone secretagogues in humans. Acta Paediatr Suppl 1997;423:92-96.
23. Thorner MO, Chapman IM, Gaylinn BD, Pezzoli SS, Hartman ML: Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging. Recent Prog Horm Res 1997;52:215-244.
24. Svensson J, Lall S, Dickson SL, Rømer J, Ahnfelt-Rønne. Ohlsson C, Jansson J-O: Effects of GH-releasing substances on bone mass in adult female rats (abstract F235). 2nd Joint Meet Am Soc for Bone Miner Res and Int Bone Miner Soc, San Francisco, 1998.
25. Mayo KE, Cerelli GM, Rosenfeld MG, Evans RM: Characterization of cDNA and genomic clones encoding the precursor to rat hypothalamic growth hormone-releasing factor. Nature 1985;314:464-467.
26. de Quidt ME, Kiyama H, Emson PC: Pancreatic polypeptide, neuropeptide Y and peptide YY in central neurones; in Bjorkland A, Hökfelt T, Kubar MJ (eds): Handbook of Chemical Neuroanatomy. Amsterdam, Elsevier, 1990, vol 9, pp 287-359.
27. Funckes CL, Minth CD, Deschenes R, Magazin M, Tavianni MA, Sheets M, Collier K, Weith HL, Aron DC, Roos BA, Dixon JE: Cloning and characterization of an mRNA-encoding rat preprosomatostatin. J Biol Chem 1983;258:8781-8787.
28. Curran T, Morgan JI: Fos: An immediate-early transcription factor in neurons. J Neurobiol 1995;26:403-412.
29. Fairhall KM, Mynett A, Robinson ICAF: Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action. J Endocrinol 1995;144:555-560.
30. Dickson SL, Viltart O, Bailey ART, Leng G: Attenuation of the growth hormone secretagogue induction of Fos protein in the rat arcuate nucleus by central somatostatin action. Neuroendocrinology 1997;66:188-194.
31. Tannenbaum GS, Ling N: The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultraradian rhythm of GH secretion. Endocrinology 1984;115:1952-1957.
32. Guan XM, Yu H, Palyha OC, McKee KK, Feighner SD, Sirinathsinghji DJS, Smith RG, Van der Ploeg LHT, Howard AD: Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Mol Brain Res 1997;48:23-29.
33. Kamegai J, Minami S, Sugihara H, Higuchi H, Wakabayashi I: Growth hormone induces expression of the c-fos gene on hypothalamic neuropeptide-Y and somatostatin neurons in hypophysectomised rats. Endocrinology 1994; 135;2765-2771.
34. Chihara K, Minamitani N, Kaji H, Arimura A, Fulita T: Intraventricularly injected growth hormone stimulates somatostatin release into the portal blood. Endocrinology 1981;109: 2279-2281.
35. Minami S, Kamegai J, Sugihara H, Hasegawa O, Wakabayashi I: Systemic injection of recombinant human growth hormone induces expression of the c-fos gene in the hypothalamic arcuate and periventricular nuclei in hypophysectomized rats. Endocrinology 1992; 131:247-253.
36. Minami S, Suzuki N, Sugihara H, Tamura H, Emoto N, Wakabayashi I: Microinjection of rat GH but not human IGF-1 into a defined area of the hypothalamus inhibits endogenous GH secretion in rats. J Endocrinol 1997;153:283-290.
37. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF: Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergistic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: Evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab 1995;80:942-947.
38. Lin S-C, Lin CR, Gukovsky I, Luis AJ, Sawchenko PE, Rosenfeld MG: Molecular basis of the little mouse phenotype and implications for cell type-specific growth. Nature 1993;364: 208-213.
39. Jansson J-O, Downs TR, Beamer WG, Frohman LA: The dwarf 'little' mouse is resistant to growth hormone (GH)-releasing peptide (GH-RP-6) as well as to GH-releasing hormone (GHR) (abstract 397). Proc 68th Annu Meet Endocr Soc 1985.
40. Tannenbaum GS, Lapointe M, Beaudet A, Howard AD: Expression of growth hormone secretagogue-receptors by growth hormone-releasing hormone cells in the mediobasal hypothalamus. Endocrinology 1998;139:4420-4423.